Debra Tompson

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of <scp>RIPK</scp>1 inhibitor <scp>GSK</scp>2982772 in healthy volunteers

Kathleen Weisel, Nicola Scott, Debra Tompson et al. · Pharmacology Research & Perspectives · 2017 · 130 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

Caryl Schwartzbach, Richard Grove, Robert A. Brown et al. · Journal of Neurology · 2016 · 113 citations · Full text

Medicine, Neurology, Pharmacology +15

Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects

Ruth Dixon, Sarah A. Job, Ruth Oliver et al. · British Journal of Clinical Pharmacology · 2008 · 112 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

Kathy Weisel, Nicola Scott, Scott B. Berger et al. · BMJ Open Gastroenterology · 2021 · 93 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Kathleen Weisel, Scott B. Berger, Katie Thorn et al. · Arthritis Research & Therapy · 2021 · 89 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15